Related references
Note: Only part of the references are listed.Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents
Muling Mao et al.
CLINICAL CANCER RESEARCH (2013)
WNT signalling pathways as therapeutic targets in cancer
Jamie N. Anastas et al.
NATURE REVIEWS CANCER (2013)
Are KRAS/BRAF Mutations Potent Prognostic and/or Predictive Biomarkers in Colorectal Cancers?
Tomoya Yokota
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2012)
Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review
Xiaoyun Liao et al.
CLINICAL CANCER RESEARCH (2012)
Combining Molecular Markers With the TNM Staging System to Improve Prognostication in Stage II and III Colon Cancer: Are We Ready Yet?
Frank A. Sinicrope et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
TNM staging of colorectal carcinoma: issues and caveats
Jinru Shia et al.
SEMINARS IN DIAGNOSTIC PATHOLOGY (2012)
Therapeutic targeting of the phosphatidyl-inositol 3-kinase signaling pathway: novel targeted therapies and advances in the treatment of colorectal cancer
Ming Yu et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Colorectal cancer molecular biology moves into clinical practice
Colin C. Pritchard et al.
GUT (2011)
Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
Nikhil Wagle et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Cancer Screening in the United States, 2010 A Review of Current American Cancer Society Guidelines and Issues in Cancer Screening
Robert A. Smith et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer
Inti Zlobec et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
Alberto Bardelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
Arnaud D. Roth et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Oncogenic mutations as predictive factors in colorectal cancer
A. Lievre et al.
ONCOGENE (2010)
Prognostic and Predictive Biomarkers in Resected Colon Cancer: Current Status and Future Perspectives for Integrating Genomics into Biomarker Discovery
Sabine Tejpar et al.
ONCOLOGIST (2010)
Serrated Polyps and Colorectal Cancer: New Pathway to Malignancy
Amy E. Noffsinger
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2009)
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
F. Loupakis et al.
BRITISH JOURNAL OF CANCER (2009)
PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies
Andrea Sartore-Bianchi et al.
CANCER RESEARCH (2009)
PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer
Hans Prenen et al.
CLINICAL CANCER RESEARCH (2009)
Randomized phase 3 study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as 1st-line treatment (tx) for metastatic colorectal cancer (mCRC): the PRIME trial
J. Douillard et al.
EJC SUPPLEMENTS (2009)
High Detection Rates of Colorectal Neoplasia by Stool DNA Testing With a Novel Digital Melt Curve Assay
Hongzhi Zou et al.
GASTROENTEROLOGY (2009)
Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review
Glenn E. Palomaki et al.
GENETICS IN MEDICINE (2009)
Immunohistochemistry staining for the mismatch repair proteins in the clinical care of patients with colorectal cancer
Christopher D. South et al.
GENETICS IN MEDICINE (2009)
CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer
Shuji Ogino et al.
GUT (2009)
KRAS and BRAF Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial
Susan D. Richman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803
Monica M. Bertagnolli et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer
Pierre Laurent-Puig et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
Carmen J. Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Amphiregulin and Epiregulin mRNA Expression in Primary Tumors Predicts Outcome in Metastatic Colorectal Cancer Treated With Cetuximab
Bart Jacobs et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
PIK3CA Mutation Is Associated With Poor Prognosis Among Patients With Curatively Resected Colon Cancer
Shuji Ogino et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
Carsten Bokemeyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor-Targeted Therapy in Metastatic Colorectal Cancer
Salvatore Siena et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Sensitive digital quantification of DNA methylation in clinical samples
Meng Li et al.
NATURE BIOTECHNOLOGY (2009)
BRAF Mutation in Metastatic Colorectal Cancer.
Jolien Tol et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Analysis of the Association between CIMP and BRAFV600E in Colorectal Cancer by DNA Methylation Profiling
Toshinori Hinoue et al.
PLOS ONE (2009)
Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer
Andrea Sartore-Bianchi et al.
PLOS ONE (2009)
Genetic prognostic and predictive markers in colorectal cancer
Axel Walther et al.
NATURE REVIEWS CANCER (2009)
A Simplified, Noninvasive Stool DNA Test for Colorectal Cancer Detection
Steven Itzkowitz et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)
Stool DNA and occult blood testing for screen detection of colorectal neoplasia
David A. Ahlquist et al.
ANNALS OF INTERNAL MEDICINE (2008)
Potential value of PTEN in predicting cetuximab response in colorectal cancer: An exploratory study
Evangelia Razis et al.
BMC CANCER (2008)
Hypermethylator Phenotype in Sporadic Colon Cancer: Study on a Population-Based Series of 582 Cases
Ludovic Barault et al.
CANCER RESEARCH (2008)
PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab
Minaxi Jhawer et al.
CANCER RESEARCH (2008)
Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer
Amy J. French et al.
CLINICAL CANCER RESEARCH (2008)
Genomic and epigenetic instability in colorectal cancer pathogenesis
William M. Grady et al.
GASTROENTEROLOGY (2008)
Functional classification analysis of somatically mutated genes in human breast and colorectal cancers
Thomas W. Chittenden et al.
GENOMICS (2008)
Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis
A. Walther et al.
GUT (2008)
Novel Mutations of the Suppressor Gene PTEN in Colorectal Carcinomas Stratified by Microsatellite Instability- and TP53 Mutation- Status
Stine A. Danielsen et al.
HUMAN MUTATION (2008)
Predicting clinical outcome of 5-fluorouracil-based chemotherapy for colon cancer patients: is the CpG island methylator phenotype the 5-fluorouracilresponsive subgroup?
Barry Iacopetta et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2008)
Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): A pooled molecular reanalysis of randomized chemotherapy trials
D. J. Sargent et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Predicting fluorouracil toxicity: Can we finally do it?
Hany H. Ezzeldin et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer
Salvatore Artale et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Federica Di Nicolantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Predictive biomarkers of chemotherapy efficacy in colorectal cancer: Results from the UK MRC FOCUS trial
Michael S. Braun et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: A prospective clinical trial by the German 5-FU toxicity study group
Matthias Schwab et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome - Part II. The utility of microsatellite instability testing
Liying Zhang
JOURNAL OF MOLECULAR DIAGNOSTICS (2008)
Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome - Part I. The utility of immunohistochemistry
Jinru Shia
JOURNAL OF MOLECULAR DIAGNOSTICS (2008)
A stochastic carcinogenesis model incorporating multiple types of genomic instability fitted to colon cancer data
Mark P. Little et al.
JOURNAL OF THEORETICAL BIOLOGY (2008)
Drug therapy: EGFR antagonists in cancer treatment
Fortunato Ciardiello et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
PI3K pathway alterations in cancer: variations on a theme
T. L. Yuan et al.
ONCOGENE (2008)
Comprehensive Biostatistical Analysis of CpG Island Methylator Phenotype in Colorectal Cancer Using a Large Population-Based Sample
Katsuhiko Nosho et al.
PLOS ONE (2008)
Loss of Smad4 protein expression and 18qLOH as molecular markers indicating lymph node metastasis in colorectal cancer - A study matched for tumor depth and pathology
Toshiaki Tanaka et al.
JOURNAL OF SURGICAL ONCOLOGY (2008)
Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer
Lanlan Shen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: Results of CALGB 89803
Leonard B. Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Distinction of hereditary nonpolyposis colorectal cancer and sporadic microsatellite-unstable colorectal cancer through quantification of MLH1 methylation by real-time PCR
Marcus Bettstetter et al.
CLINICAL CANCER RESEARCH (2007)
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
F. Di Fiore et al.
BRITISH JOURNAL OF CANCER (2007)
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies
Silvia Benvenuti et al.
CANCER RESEARCH (2007)
Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study
George P. Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Improved fecal DNA test for colorectal cancer screening
Steven H. Itzkowitz et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2007)
Chromosomal instability correlates with genome-wide DNA demethylation in human primary colorectal cancers
Jairo Rodriguez et al.
CANCER RESEARCH (2006)
CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer
Daniel J. Weisenberger et al.
NATURE GENETICS (2006)
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
A Lièvre et al.
CANCER RESEARCH (2006)
Genetic clonal diversity predicts progression to esophageal adenocarcinoma
CC Maley et al.
NATURE GENETICS (2006)
The relationship between global methylation level, loss of heterozygosity, and microsatellite instability in sporadic colorectal cancer
K Matsuzaki et al.
CLINICAL CANCER RESEARCH (2005)
Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma:: an immunohistochemical and chromogenic in situ hybridization study
J Shia et al.
MODERN PATHOLOGY (2005)
BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors
N Lubomierski et al.
CANCER (2005)
SMAD4 levels and response to 5-fluorouracil in colorectal cancer
P Alhopuro et al.
CLINICAL CANCER RESEARCH (2005)
Screening for the Lynch syndrome (Hereditary nonpolyposis colorectal cancer).
H Hampel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
SMAD4 as a prognostic marker in colorectal cancer
H Alazzouzi et al.
CLINICAL CANCER RESEARCH (2005)
Drug therapy - Systemic therapy for colorectal cancer
JA Meyerhardt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Stool screening for colorectal cancer: Molecular approaches
NK Osborn et al.
GASTROENTEROLOGY (2005)
Use of microsatellite instability and immunohistochemistry testing for the identification of individuals at risk for Lynch syndrome
LM Baudhuin et al.
FAMILIAL CANCER (2005)
Systematic review of microsatellite instability and colorectal cancer prognosis
S Popat et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
High frequency of mutations of the PIK3CA gene in human cancers
Y Samuels et al.
SCIENCE (2004)
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor
LB Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing
E Domingo et al.
JOURNAL OF MEDICAL GENETICS (2004)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Activin type II receptor restoration in ACVR2-deficient colon cancer cells induces transforming growth factor-β response pathway genes
E Deacu et al.
CANCER RESEARCH (2004)
Development of a fluorescent multiplex assay for detection of MSI-high tumors
JW Bacher et al.
DISEASE MARKERS (2004)
Proximal versus distal hyperplastic polyps of the colorectum: different lesions or a biological spectrum?
K Baker et al.
JOURNAL OF CLINICAL PATHOLOGY (2004)
Hyperplastic Polyps and Colorectal Cancer: Is There a Link?
Jeremy R. Jass
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2004)
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer
CM Ribic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Molecular changes in the Ki-ras and APC genes in primary colorectal carcinoma and synchronous metastases compared with the findings in accompanying adenomas
P Zauber et al.
JOURNAL OF CLINICAL PATHOLOGY-MOLECULAR PATHOLOGY (2003)
Mutational analysis of the tyrosine kinome in colorectal cancers
A Bardelli et al.
SCIENCE (2003)
A randomized trial of aspirin to prevent colorectal adenomas
JA Baron et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Targeting ras signalling pathways in cancer therapy
J Downward
NATURE REVIEWS CANCER (2003)
High-frequency microsatellite instability predicts better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection
JT Liang et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Colorectal adenoma to carcinoma progression follows multiple pathways of chromosomal instability
M Hermsen et al.
GASTROENTEROLOGY (2002)
SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer
JL Boulay et al.
BRITISH JOURNAL OF CANCER (2002)
Tumorigenesis -: RAF/RAS oncogenes and mismatch-repair status
H Rajagopalan et al.
NATURE (2002)
Molecular predictors of survival after adjuvant chemotherapy for colon cancer.
T Watanabe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Histopathological identification of colon cancer with microsatellite instability
J Alexander et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
The genetic basis of colorectal cancer: Insights into critical pathways of tumorigenesis
DC Chung
GASTROENTEROLOGY (2000)
Share Paper
